Changing respiratory health forever
RESPINOR is developing a novel, non-invasive, ultrasound-based medical device, DXT (Diaphragm Excursion Technology), to improve clinical decision-making in critically ill patients. DXT has the first ultrasound sensors that can stick to the skin for continuous monitoring of our main breathing muscle, the diaphragm. The diaphragm is as critical to our respiratory system as the heart is to the cardiovascular system. There are no standardized and objective technologies for continuous diaphragm monitoring available. RESPINOR’s technology is the winner of Horizon 2020 funding both in phase I and II. The company has successfully completed clinical feasibility studies in Europe for the first target segment mechanical ventilation (MV) with technical proof of principle and proof of concept confirmed. Our technology has a broad range of potential benefits and represents a technology platform for applications in critical care and other areas of respiratory medicine.
RESPINOR has started the last phase of the clinical program, DE-RISK-WF study in Europe, with DXT before regulatory submission (EU and USA)
“I think it sounds highly innovative, especially because it allows for standardized observation and assessment of patients, involving very little effort and, above all, it's non-invasive. I find that very appealing.”ICU Specialist Germany
RESPINOR develops innovative products for monitoring of respiratory function. RESPINOR is dedicated to providing uncompromised quality products that are safe and cost-effective to health care systems.
We understand that listening to customer needs and meeting market needs are key to continued product improvement.
RESPINOR is committed to maintaining an effective quality management system compliant with all applicable regulations in countries where our products are developed, manufactured and sold.